Premier Biomedical Inc (BIEI) financial statements (2020 and earlier)

Company profile

Business Address P.O. BOX 25
JACKSON CENTER, PA 16133
State of Incorp. NV
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1178784223510316
Cash and cash equivalents1178784223510316
Receivables330 37  
Inventory, net of allowances, customer advances and progress billings212685   
Inventory212685    
Prepaid expense   11996
Other current assets364435    
Other undisclosed current assets    (16)3 
Total current assets:178160204346711622
Noncurrent Assets
Property, plant and equipment8555454
Total noncurrent assets:8555454
TOTAL ASSETS:186165209397012125
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities242286353239196147122
Accounts payable193264347221188147122
Interest and dividends payable49226188  
Debt192310170303015109
Due to related parties3126418285  
Other undisclosed current liabilities1,8391,6902,256348362643
Total current liabilities:2,3042,3122,820700347188275
Noncurrent Liabilities
Total liabilities:2,3042,3122,820700347188275
Stockholders' equity
Stockholders' equity attributable to parent, including:(2,118)(2,147)(2,611)(661)(276)(68)(249)
Preferred stock 222   
Common stock0063100
Additional paid in capital14,94714,57313,43611,90010,5018,1286,536
Accumulated deficit(17,068)(16,728)(16,329)(12,565)(10,778)(8,196)(6,785)
Other undisclosed stockholders' equity attributable to parent25274    
Total stockholders' equity:(2,118)(2,147)(2,611)(661)(276)(68)(249)
TOTAL LIABILITIES AND EQUITY:186165209397012125

Income statement (P&L) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues224040 10  
Net investment income    10  
Cost of revenue(99)(114)(25)    
Cost of goods and services sold (88)(25)    
Gross profit:(77)(74)14 10  
Operating expenses(605)(619)(1,304)(638)(2,383)(1,369)(4,477)
Other undisclosed operating loss    (10)  
Operating loss:(682)(693)(1,290)(638)(2,383)(1,369)(4,477)
Nonoperating income (expense)(160)294(2,474)(1,130)(199)(42)(400)
Interest and debt expense(195)(415)(352)(817)(199)(42)(400)
Loss before gain (loss) on sale of properties:(1,037)(814)(4,115)(2,586)(2,781)(1,452)(5,278)
Other undisclosed net income    19942400
Net loss:(1,037)(814)(4,115)(2,586)(2,582)(1,411)(4,877)
Other undisclosed net income attributable to parent195415352817   
Net loss available to common stockholders, diluted:(842)(399)(3,764)(1,768)(2,582)(1,411)(4,877)

Comprehensive Income ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(1,037)(814)(4,115)(2,586)(2,582)(1,411)(4,877)
Comprehensive loss, net of tax, attributable to parent:(1,037)(814)(4,115)(2,586)(2,582)(1,411)(4,877)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: